Abstract 1956P
Background
Alternative promoters and splice sites enable most human genes to generate multiple transcript isoforms, significantly increasing phenotypic complexity. Large-scale tumor RNA-seq analysis has demonstrated widespread splicing aberrations and alternative promoter activation in cancer, implicating isoform dysregulation as a crucial factor in carcinogenesis.
Methods
By integrating RNA-seq data from TCGA, PCAWG, and GTEx projects, we reconstructed individual transcript sequences expressed in more than 26000 cancer and normal samples, elucidating a comprehensive panorama of alternative isoform utilization across 39 tissues and 38 cancer types.
Results
Our isoform-centric analysis reveals that (1) global transcriptome architecture is distinct across tissues, between cancer and normal samples of the same tissue origin, and between cancer molecular subtypes—even at sub-gene resolution; (2) alternative promoter usage and splicing together contribute to ∼40% of transcriptome heterogeneity across tissues and 50-60% within tissues and cancer types; (3) cancer frequently increases the usage of aberrant tumor suppressor gene isoforms lacking protein-coding potential; (4) differentially used isoforms hold significant prognostic value in various cancers, with aberrant transcripts from NRG1, CAMTA1, and LRP1B demonstrating the strongest association with survival; and (5) co-occurring differential splicing events within single RNA molecules may offset each other's frame-shifting effects.
Conclusions
Our findings indicate cancer frequently dysregulates alternative isoform usage, perturbing key oncogenic pathways. This highlights the value of isoform-resolution transcriptome profiling for improved individualized cancer diagnostics and treatment strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Korea Advanced Institute of Science and Technology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1988P - Enfortumab vedotin (EV) + pembrolizumab (P) outcomes outside clinical trials and biomarkers of benefit in patients (pts) with advanced urothelial carcinoma: Analysis of the UNITE study
Presenter: Tanya Jindal
Session: Poster session 13
1989P - Efficacy of enfortumab vedotin (EV) in patients (pts) with (w) advanced urothelial carcinoma (aUC) who have baseline neuropathy (N) and/or diabetes mellitus (DM): A UNITE study analysis
Presenter: Albert Jang
Session: Poster session 13
1990P - MRG002-HER2 ADC combined with pucotenlimab (a PD-1 inhibitor), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase I/II study
Presenter: Chuanliang Cui
Session: Poster session 13
1992P - Real-world (RW) characteristics and outcomes in patients (pts) with muscle-invasive urothelial carcinoma (MIUC) treated with adjuvant nivolumab (NIVO) with or without neoadjuvant chemotherapy (NAC)
Presenter: Hedyeh Ebrahimi
Session: Poster session 13
1993P - A randomized, phase II trial to evaluate the safety and efficacy of eribulin mesylate in combination with atezolizumab compared to atezolizumab alone in subjects with locally advanced or metastatic transitional cell urothelial cancer where cisplatin-based treatment is not an option
Presenter: Anishka D'Souza
Session: Poster session 13
1994P - Updated efficacy profile of the double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) in ≥ second line in metastatic urothelial carcinoma (mUC)
Presenter: Bradley McGregor
Session: Poster session 13
1995P - Insights into second-line (2L) systemic treatment (tx) receipt in patients (pts) with metastatic urothelial carcinoma (mUC): Results of a retrospective observational study in Germany
Presenter: Günter Niegisch
Session: Poster session 13
1996P - Primary analysis of post-marketing surveillance (PMS) data for avelumab maintenance therapy in patients (pts) with curatively unresectable urothelial carcinoma (UC) in Japan
Presenter: Eiji Kikuchi
Session: Poster session 13
1997P - Novel biomarker, ephrinB2 (B2), predicts resistance to treatment and poor overall survival (OS) metastatic urothelial carcinoma (mUC)
Presenter: Sarmad Sadeghi
Session: Poster session 13